News articles about iCo Therapeutics (OTCMKTS:ICOTF) have trended somewhat positive on Saturday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 6,000 news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. iCo Therapeutics earned a news sentiment score of 1.47 on their scale. InfoTrie also gave press coverage about the biotechnology company an news buzz score of 10 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock’s share price in the near future.
ICOTF stock remained flat at $$0.04 during trading on Friday. The stock has a fifty day moving average price of $0.05. iCo Therapeutics has a 12-month low of $0.03 and a 12-month high of $0.20.
iCo Therapeutics Company Profile
iCo Therapeutics Inc, a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections.
Featured Story: How to Use a Moving Average for Trading
Receive News & Ratings for iCo Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for iCo Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.